By Professor Michael Leonard Friedlander

Journal articles

Arun BK; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bell-McGuinn KM; Bach BA; Kundu MG; Ratajczak CK; Maag D; Diéras V, 2021, 'Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial', European Journal of Cancer, 154, pp. 35 - 45, http://dx.doi.org/10.1016/j.ejca.2021.05.037

Quinn MCJ; McCue K; Shi W; Johnatty SE; Beesley J; Civitarese A; O'Mara TA; Glubb DM; Tyrer JP; Armasu SM; Ong JS; Gharahkhani P; Lu Y; Gao B; Patch AM; Fasching PA; Beckmann MW; Lambrechts D; Vergote I; Velez Edwards DR; Beeghly-Fadiel A; Benitez J; Garcia MJ; Goodman MT; Dörk T; Dürst M; Modugno F; Moysich K; Du Bois A; Pfisterer J; Bauman K; Karlan BY; Lester J; Cunningham JM; Larson MC; McCauley BM; Kjaer SK; Jensen A; Hogdall CK; Hogdall E; Schildkraut JM; Riggan MJ; Berchuck A; Cramer DW; Terry KL; Bjorge L; Webb PM; Friedlander M; Pejovic T; Moffitt M; Glasspool R; May T; Ene GEV; Huntsman DG; Woo M; Carney ME; Hinsley S; Heitz F; Fereday S; Kennedy CJ; Edwards SL; Winham SJ; DeFazio A; Pharoah PDP; Goode EL; MacGregor S; Chenevix-Trench G, 2021, 'Identification of a locus near ULK1 associated with progression-free survival in ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 1669 - 1680, http://dx.doi.org/10.1158/1055-9965.EPI-20-1817

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E, 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', Obstetrical and Gynecological Survey, 76, pp. 535 - 536, http://dx.doi.org/10.1097/OGX.0000000000000962

Tjokrowidjaja A; Friedlander M; Lord SJ; Asher R; Rodrigues M; Ledermann JA; Matulonis UA; Oza AM; Bruchim I; Huzarski T; Gourley C; Harter P; Vergote I; Scott CL; Meier W; Shapira-Frommer R; Milenkova T; Pujade-Lauraine E; Gebski V; Lee CK, 2021, 'Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy', European Journal of Cancer, 154, pp. 190 - 200, http://dx.doi.org/10.1016/j.ejca.2021.06.024

Aghajanian C; Bookman MA; Fleming GF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Jackson CG; Sullivan D; Ratajczak CK; Coleman RL, 2021, 'Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial', Gynecologic Oncology, 162, pp. 375 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.05.031

Xu X; Wang Y; Bryce NS; Tang K; Meagher NS; Kang EY; Kelemen LE; Köbel M; Ramus SJ; Friedlander M; Ford CE; Hardeman EC; Gunning PW, 2021, 'Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents', British Journal of Cancer, 125, pp. 265 - 276, http://dx.doi.org/10.1038/s41416-021-01420-y

Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL, 2021, 'Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis', Cancer, 127, pp. 2432 - 2441, http://dx.doi.org/10.1002/cncr.33517

Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L, 2021, 'Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial', Journal for ImmunoTherapy of Cancer, 9, http://dx.doi.org/10.1136/jitc-2020-002255

Kurtz JE; Gebski V; Sukhin V; Carey M; Kong I; Glasspool RM; Berek JS; de Paiva Batista M; Hall M; Kim JW; Yeoshoua E; Fujiwara N; Nam BH; Polleis S; Lee JY; Strojna A; Farrelly L; Schwameis R; Fossati R; Darlington AS; Lai CH; Wright AA; Rosenblat O; Harter P; Roxburgh P; Chowdhury RR; Chang TC; Paoletti X; Friedlander M, 2021, 'Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee', Gynecologic Oncology, 161, pp. 502 - 507, http://dx.doi.org/10.1016/j.ygyno.2021.02.018

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E; Byrski T; Pautier P; Harter P; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Poveda Velasco A; Rodrigues M; Lotz JP; Selle F; Ray-Coquard I; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Yunokawa M; Medioni J; Pécuchet N; Dubot C; De La Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Banerjee S; Cosin J; Hoffman J; Plante M; Covens A; Joly F; Hirte H; Amit A; Matsumoto K; Tjulandin S; Hoon Kim J; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez De Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I; Sikorska M; Słowińska A; Rogowski W; Bidziński M; Śpiewankiewicz B, 2021, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 22, pp. 620 - 631, http://dx.doi.org/10.1016/S1470-2045(21)00073-5

Friedlander M; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Lisyanskaya A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley WH; Liu J; Mathews C; Selle F; Lortholary A; Lowe ES; Hettle R; Flood E; Parkhomenko E; DiSilvestro P, 2021, 'Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial', The Lancet Oncology, 22, pp. 632 - 642, http://dx.doi.org/10.1016/S1470-2045(21)00098-X

Francis KE; Gebski V; Lord SJ; Friedlander M; Pujade-Lauraine E; Lee CK, 2021, 'Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting', European Journal of Cancer, 148, pp. 251 - 259, http://dx.doi.org/10.1016/j.ejca.2021.02.006

Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML, 2021, 'REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer', Gynecologic Oncology, 161, pp. 374 - 381, http://dx.doi.org/10.1016/j.ygyno.2021.02.002

Timmins HC; Li T; Trinh T; Kiernan MC; Harrison M; Boyle F; Friedlander M; Goldstein D; Park SB, 2021, 'Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response', Oncologist, 26, pp. 366 - 374, http://dx.doi.org/10.1002/onco.13697

Evans DG; Phillips KA; Milne RL; Fruscio R; Cybulski C; Gronwald J; Lubinski J; Huzarski T; Hyder Z; Forde C; Metcalfe K; Senter L; Weitzel J; Tung N; Zakalik D; Ekholm M; Sun P; Narod SA; Blasinska-Morawiec M; Chosia M; Drosik K; Gozdecka-Grodecka S; Gozdz S; Grzybowska E; Jeziorski A; Karczewska A; Kordek R; Synowiec A; Kozak-Klonowska B; Lamperska K; Lange D; Mackiewicz A; Mitus JW; Niepsuj S; Oszurek O; Gugala K; Morawiec Z; Mierzwa T; Posmyk M; Rys J; Szczylik C; Ucinski M; Urbanski K; Wasko B; Wandzel P; Friedlander M; McLachlan SA; Nesci S; Picken S; O’Connor S; Stanhope L; Eisen A; Sweet K; Kim R; Foulkes W; Moller P; Neuhausen S; Cullinane C; Eng C; Ainsworth P; Couch F; Singer C; Karlan B; McKinnon W; Wood M, 2021, 'Survival from breast cancer in women with a BRCA2 mutation by treatment', British Journal of Cancer, 124, pp. 1524 - 1532, http://dx.doi.org/10.1038/s41416-020-01164-1

Ledermann JA; Embleton-Thirsk AC; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Oza A; Vaughan M; Friedlander M; González-Martín A; Deane E; Popoola B; Farrelly L; Swart AM; Kaplan RS; Parmar MKB, 2021, 'Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial', ESMO Open, 6, http://dx.doi.org/10.1016/j.esmoop.2020.100043

MacDonald C; Mazza D; Hickey M; Hunter M; Keogh LA; Jones SC; Saunders C; Nesci S; Milne RL; McLachlan SA; Hopper JL; Friedlander ML; Emery J; Phillips KA, 2021, 'Motivators of Inappropriate Ovarian Cancer Screening: A Survey of Women and Their Clinicians', JNCI Cancer Spectrum, 5, http://dx.doi.org/10.1093/jncics/pkaa110

Trinh T; Park SB; Murray J; Pickering H; Lin CSY; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV, 2021, 'Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial', Supportive Care in Cancer, 29, pp. 1103 - 1110, http://dx.doi.org/10.1007/s00520-020-05591-x

Macdonald C; Saunders CM; Keogh LA; Hunter M; Mazza D; McLachlan SA; Jones SC; Nesci S; Friedlander ML; Hopper JL; Emery JD; Hickey M; Milne RL; Phillips KA, 2021, 'Breast cancer chemoprevention: Use and views of australian women and their clinicians', Cancer Prevention Research, 14, pp. 131 - 144, http://dx.doi.org/10.1158/1940-6207.CAPR-20-0369

Cameron B; Webber K; Li H; Bennett BK; Boyle F; de Souza P; Wilcken N; Lynch J; Friedlander M; Goldstein D; Lloyd AR, 2021, 'Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study', Brain, Behavior, and Immunity - Health, 10, pp. 100189, http://dx.doi.org/10.1016/j.bbih.2020.100189

Al Ramadhani RM; Nagle CM; Ibiebele TI; Grant P; Friedlander M; De Fazio A; Webb PM, 2021, 'Pre- And post-diagnosis diet quality and ovarian cancer survival', Cancer Epidemiology Biomarkers and Prevention, 30, pp. 229 - 232, http://dx.doi.org/10.1158/1055-9965.EPI-20-1036

Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; Chenevix-Trench G; Green A; Webb P; De Fazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Bergh TV; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Pavlakis N, 2021, 'Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses', Modern Pathology, 34, pp. 194 - 206, http://dx.doi.org/10.1038/s41379-020-0618-9

Lux MP; Ciani O; Dunlop WCN; Ferris A; Friedlander M, 2021, 'The impasse on overall survival in oncology reimbursement decision-making: How can we resolve this?', Cancer Management and Research, 13, pp. 8457 - 8471, http://dx.doi.org/10.2147/CMAR.S328058

Kok PS; Yoon WH; Lord S; Marschner I; Friedlander M; Lee CK, 2021, 'Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis', JCO Precision Oncology, 5, pp. 1151 - 1159, http://dx.doi.org/10.1200/PO.21.00108

Hansen JM; Nagle CM; Ibiebele TI; Grant PT; Obermair A; Friedlander ML; DeFazio A; Webb PM, 2020, 'A healthy lifestyle and survival among women with ovarian cancer', International Journal of Cancer, 147, pp. 3361 - 3369, http://dx.doi.org/10.1002/ijc.33155

Tjokrowidjaja A; Lee CK; Friedlander M; Gebski V; Gladieff L; Ledermann J; Penson R; Oza A; Korach J; Huzarski T; Manso L; Pisano C; Asher R; Lord SJ; Kim SI; Lee JY; Colombo N; Park-Simon TW; Fujiwara K; Sonke G; Vergote I; Kim JW; Pujade-Lauraine E, 2020, 'Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy', European Journal of Cancer, 139, pp. 59 - 67, http://dx.doi.org/10.1016/j.ejca.2020.08.021

DiSilvestro P; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian CA; Bradley WH; Mathews CA; Liu J; Lowe ES; Bloomfield R; Moore KN, 2020, 'Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial', Journal of Clinical Oncology, 38, pp. 3528 - 3537, http://dx.doi.org/10.1200/JCO.20.00799

Macdonald C; Mazza D; Hunter M; Keogh LA; Milne R; Hickey M; Saunders C; McLachlan SA; Friedlander M; Hopper J; Emery J; Jones S; Phillips KA, 2020, 'Chemoprevention for breast cancer: A survey of the views of Australian women and clinicians', European Journal of Cancer, 138, pp. S8, http://dx.doi.org/10.1016/S0959-8049(20)30547-5

Barnes DR; Rookus MA; McGuffog L; Leslie G; Mooij TM; Dennis J; Mavaddat N; Adlard J; Ahmed M; Aittomäki K; Andrieu N; Andrulis IL; Arnold N; Arun BK; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Benitez J; Berthet P; Białkowska K; Blanco AM; Blok MJ; Bonanni B; Boonen SE; Borg Å; Bozsik A; Bradbury AR; Brennan P; Brewer C; Brunet J; Buys SS; Caldés T; Caligo MA; Campbell I; Christensen LL; Chung WK; Claes KBM; Colas C; Collonge-Rame MA; Delnatte C; Faivre L; Giraud S; Lasset C; Mari V; Mebirouk N; Mouret-Fourme E; Schuster H; Stoppa-Lyonnet D; Antoniou A; Cook J; Davidson R; Easton D; Eeles R; Evans DG; Frost D; Hanson H; Izatt L; Ong KR; Side L; O’Shaughnessy-Kirwan A; Tischkowitz M; Walker L; Daly MB; de la Hoya M; de Putter R; Devilee P; Diez O; Ding YC; Domchek SM; Dorfling CM; Dumont M; Ejlertsen B; Engel C; Foretova L; Fostira F; Friedlander M; Friedman E; Ganz PA; Garber J; Gehrig A; Gerdes AM; Gesta P; Glendon G; Godwin AK; Goldgar DE, 2020, 'Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants', Genetics in Medicine, 22, pp. 1653 - 1666, http://dx.doi.org/10.1038/s41436-020-0862-x

Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK, 2020, 'Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, 21, pp. 1269 - 1282, http://dx.doi.org/10.1016/S1470-2045(20)30447-2

Beesley VL; Webber K; Nagle CM; DeFazio A; Obermair A; Williams M; Friedlander M; Webb PM, 2020, 'When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer', Gynecologic Oncology, 159, pp. 179 - 186, http://dx.doi.org/10.1016/j.ygyno.2020.07.029

Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK, 2020, 'Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis', JAMA Network Open, 3, pp. E2011809, http://dx.doi.org/10.1001/jamanetworkopen.2020.11809

Ross TL; DeFazio A; Friedlander M; Grant P; Nagle CM; Williams M; Webb PM; Beesley VL, 2020, 'Insomnia and its association with quality of life in women with ovarian cancer', Gynecologic Oncology, 158, pp. 760 - 768, http://dx.doi.org/10.1016/j.ygyno.2020.06.500

Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; Bowtell DD; Chenevix-Trench G; Green A; Webb P; deFazio A; Gertig D; Traficante N; Fereday S; Moore S; Hung J; Harrap K; Sadkowsky T; Pandeya N; Malt M; Mellon A; Robertson R; Vanden Bergh T; Jones M; Mackenzie P; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Ferguson K; Martin K; Martyn A; Ranieri B; White J; Jayde V; Mamers P; Bowes L; Galletta L; Giles D; Hendley J; Alsop K; Schmidt T; Shirley H; Ball C; Young C; Viduka S; Tran H; Bilic S; Glavinas L; Brooks J; Stuart-Harris R; Kirsten F; Rutovitz J; Clingan P; Glasgow A; Proietto A; Braye S; Otton G; Shannon J; Bonaventura T; Stewart J; Begbie S; Friedlander M; Bell D; Baron-Hay S; Ferrier,a A; Gard G; Nevell D; Pavlakis N; Valmadre S; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D, 2020, 'Prognostic gene expression signature for high-grade serous ovarian cancer', Annals of Oncology, 31, pp. 1240 - 1250, http://dx.doi.org/10.1016/j.annonc.2020.05.019

Ngoi NYL; Heong V; Ow S; Chay WY; Kim HS; Choi CH; Goss G; Goh JC; Tai BC; Lim DGZ; Kaliaperumal N; Au VB; Connolly JE; Kim JW; Friedlander M; Kim K; Tan DSP, 2020, 'A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)', International Journal of Gynecological Cancer, 30, pp. 1239 - 1242, http://dx.doi.org/10.1136/ijgc-2020-001604

Gleeson M; Kentwell M; Meiser B; Do J; Nevin S; Taylor N; Barlow-Stewart K; Kirk J; James P; Scott CL; Williams R; Gamet K; Burke J; Murphy M; Antill YC; Pearn A; Pachter N; Ebzery C; Poplawski N; Friedlander M; Tucker KM, 2020, 'The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients', Gynecologic Oncology, 158, pp. 431 - 439, http://dx.doi.org/10.1016/j.ygyno.2020.05.001

Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G, 2020, 'Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study', Gynecologic Oncology, 158, pp. 47 - 53, http://dx.doi.org/10.1016/j.ygyno.2020.04.706

Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B, 2020, 'Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors', Journal of Clinical Oncology, 38, pp. 2140 - 2150, http://dx.doi.org/10.1200/JCO.19.02654

Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M, 2020, 'Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors', Journal for ImmunoTherapy of Cancer, 8, http://dx.doi.org/10.1136/jitc-2019-000453

Tjokrowidjaja A; Lee CK; Friedlander M; Gebski V; Gladieff L; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Manso L; Pisano C; Asher R; Colombo N; Park-Simon T-W; Fujiwara K; Sonke GS; Vergote I; Kim J-W; Pujade-Lauraine E, 2020, 'Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy.', Journal of Clinical Oncology, 38, pp. 6014 - 6014, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6014

Trillsch F; Mahner S; Ataseven B; Asher R; Dubot C; Clamp AR; Penson RT; Oza AM; Amit A; Huzarski T; Casado A; Scambia G; Friedlander M; Colombo N; Fujiwara K; Sonke GS; denys H; Lowe ES; Pujade-Lauraine E, 2020, 'Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study.', Journal of Clinical Oncology, 38, pp. 6068 - 6068, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6068

Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon T-W; Sonke GS; Lisyanskaya AS; Kim J-H; Filho EA; Vergote I; Rowe P; Pujade-Lauraine E, 2020, 'Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.', Journal of Clinical Oncology, 38, pp. 6002 - 6002, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6002

Aghajanian C; Bookman MA; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Sullivan DM; Fallstrom M; Dinh M; Ratajczak C; Coleman RL, 2020, 'PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).', Journal of Clinical Oncology, 38, pp. 6077 - 6077, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6077

Han HS; Arun B; Kaufman B; Wildiers H; Friedlander M; Ayoub J-PM; Puhalla SL; Bach BA; Dudley M; Kundu MG; Maag D; Ratajczak C; Dieras V, 2020, 'Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin/paclitaxel (CP) in patients with gBRCA-associated advanced breast cancer: Exploratory results from BROCADE3.', Journal of Clinical Oncology, 38, pp. 1091 - 1091, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1091

Puhalla SL; Dieras V; Arun B; Kaufman B; Wildiers H; Han HS; Ayoub J-PM; Stearns V; Yuan Y; Helsten TL; Riley-Gillis B; Murphy E; Kundu MG; Wu M; Maag D; Ratajczak C; Ramathal C; Friedlander M, 2020, 'Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3.', Journal of Clinical Oncology, 38, pp. 1097 - 1097, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1097

Macinnis RJ; Liao Y; Knight JA; Milne RL; Whittemore AS; Chung WK; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; McLachlan SA; Weideman PC; Nesci S; Friedlander ML; Glendon G; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB, 2020, 'Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results', Journal of the National Cancer Institute, 112, pp. 418 - 422, http://dx.doi.org/10.1093/jnci/djz194

Kasherman L; Siu DHW; Lee KWC; Lord S; Marschner I; Lewis CR; Friedlander M; Lee CK, 2020, 'Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: A meta-analysis', Journal of Geriatric Oncology, 11, pp. 508 - 514, http://dx.doi.org/10.1016/j.jgo.2019.05.013

Heinzelmann-Schwarz V; Kind AB; Vetter M; Russell K; Omar S; Schoetzau A; Hoeck K; Fink D; Friedlander ML; Hacker NF, 2020, 'Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?', Journal of Cancer Research and Clinical Oncology, 146, pp. 695 - 704, http://dx.doi.org/10.1007/s00432-019-03091-y

Li H; Terry MB; Antoniou AC; Phillips KA; Kast K; Mooij TM; Engel C; Nogues C; Stoppa-Lyonnet D; Lasset C; Berthet P; Mari V; Caron O; Barrowdale D; Frost D; Brewer C; Evans DG; Izatt L; Side L; Walker L; Tischkowitz M; Rogers MT; Porteous ME; Snape K; Meijers-Heijboer HEJ; Gille JJP; Blok MJ; Hoogerbrugge N; Daly MB; Andrulis IL; Buys SS; John EM; McLachlan SA; Friedlander M; Tan YY; Osorio A; Caldes T; Jakubowska A; Simard J; Singer CF; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Arver B; Olsson H; Schmutzler RK; Hopper JL; Milne RL; Easton DF; Van Leeuwen FE; Rookus MA; Andrieu N; Goldgar DE, 2020, 'Alcohol consumption, cigarette smoking, and risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Results from the BRCA1 and BRCA2 cohort consortium', Cancer Epidemiology Biomarkers and Prevention, 29, pp. 368 - 378, http://dx.doi.org/10.1158/1055-9965.EPI-19-0546

Roncolato FT; O'Connell RL; Joly F; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Salutari V; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Fehm T; Ledermann J; Roemer-Becuwe C; Stockler MR; King MT; Friedlander ML, 2020, 'Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)', Gynecologic Oncology, 156, pp. 45 - 53, http://dx.doi.org/10.1016/j.ygyno.2019.10.001

Back to profile page